Celgene Corporation is a drug manufacturers - general business based in the US. Celgene Corporation shares (CELG) are listed on the NASDAQ and all prices are listed in US Dollars. Celgene Corporation employs 8,852 staff and has a trailing 12-month revenue of around $17 billion.
Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Probability percentage is subject to decrease.
Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.
Trade stocks, ETFs, options, futures and bonds all in one place
$0 commissions on stocks, ETFs and equity options, with low contract fees
Deposit or transfer $10,000+ to earn a 2% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&C apply.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Celgene Corporation stock price (NASDAQ: CELG)
Use our graph to track the performance of CELG stocks over time.
Is it a good time to buy Celgene Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Is Celgene Corporation stock undervalued or overvalued?
Valuing Celgene Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Celgene Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Celgene Corporation's P/E ratio
Celgene Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Celgene Corporation shares trade at around 13x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Celgene Corporation's PEG ratio
Celgene Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.86. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Celgene Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Celgene Corporation's EBITDA
Celgene Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $8.9 billion.
The EBITDA is a measure of a Celgene Corporation's overall financial performance and is widely used to measure a its profitability.
Celgene Corporation financials
Revenue TTM
$17 billion
Operating margin TTM
48.75%
Gross profit TTM
$14.1 billion
Return on assets TTM
13.69%
Return on equity TTM
69.39%
Profit margin
34.63%
Book value
$16.99
Market Capitalization
$77 billion
TTM: trailing 12 months
Celgene Corporation's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Celgene Corporation.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Celgene Corporation's total ESG risk score
Total ESG risk: 23.71
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Celgene Corporation's overall score of 23.71 (as at 12/31/2018) is excellent – landing it in it in the 3rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Celgene Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Celgene Corporation's environmental score
Environmental score: 1.02/100
Celgene Corporation's environmental score of 1.02 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Celgene Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Celgene Corporation's social score
Social score: 14.4/100
Celgene Corporation's social score of 14.4 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Celgene Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Celgene Corporation's governance score
Governance score: 5.29/100
Celgene Corporation's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Celgene Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Celgene Corporation's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Celgene Corporation scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Celgene Corporation has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Celgene Corporation was last rated for ESG on: 2019-01-01.
Total ESG score
23.71
Total ESG percentile
2.75
Environmental score
1.02
Environmental score percentile
2
Social score
14.4
Social score percentile
2
Governance score
5.29
Governance score percentile
2
Level of controversy
2
Celgene Corporation share dividends
We're not expecting Celgene Corporation to pay a dividend over the next 12 months.
Have Celgene Corporation's shares ever split?
Celgene Corporation's shares were
split on a 2:1 basis on 25 June 2014
. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Celgene Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Celgene Corporation shares which in turn could have impacted Celgene Corporation's share price.
Celgene Corporation share price volatility
Over the last 12 months, Celgene Corporation's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celgene Corporation's is 1.4131. This would suggest that Celgene Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Celgene Corporation overview
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc. ; Agios Pharmaceuticals, Inc. ; bluebird bio, Inc.
Frequently asked questions
null What percentage of Celgene Corporation is owned by institutions? Currently 78% of Celgene Corporation shares are held by institutions.How many people work for Celgene Corporation? Latest data suggests 8,852 work at Celgene Corporation.When does the fiscal year end for Celgene Corporation? Celgene Corporation's fiscal year ends in December.Where is Celgene Corporation based? Celgene Corporation's address is: 86 Morris Avenue, Summit, NJ, United States, 07901What is Celgene Corporation's ISIN number? Celgene Corporation's international securities identification number is: US1510201049What is Celgene Corporation's CUSIP number? Celgene Corporation's Committee on Uniform Securities Identification Procedures number is: 151020104
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
